Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis

BACKGROUND: This study aimed to explore the molecular mechanism and clinical relevance of iguratimod in the regulation of human B cell terminal differentiation. METHODS: An in vitro human antibody-secreting cell (ASC) differentiation system was established to test the effect of iguratimod. B cell ph...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Res Ther
Hlavní autoři: Ye, Yan, Liu, Mei, Tang, Longhai, Du, Fang, Liu, Yuanhua, Hao, Pei, Fu, Qiong, Guo, Qiang, Yan, Qingran, Zhang, Xiaoming, Bao, Chunde
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6458835/
https://ncbi.nlm.nih.gov/pubmed/30971291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-019-1874-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky